Urogen Pharma Ltd. (URGN)
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.55 per share a year ago.
UroGen: Expect Rough Patch Before Strong Recovery In 2026
UroGen Pharma is revisited after a previous Strong Buy rating, with UroGen having increased ~95% since then. The article reflects on UroGen's RTGel technology, which supports JELMYTO and ZUSDURI, its two FDA-approved products. JELMYTO has grown its revenues, but they are starting to taper off.
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UroGen Pharma: Targeting Profits In 2027
UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy ratings and price targets between $31 and $47, reflecting optimism about the company's growth trajectory. Despite growing sales, UroGen continues to post net losses and will likely require a capital raise to support the Zusduri launch.
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Elizabeth A.
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.91 per share a year ago.
UroGen Pharma: Lessons Learned And Future Outlook
UroGen Pharma's FDA approval for UGN-102 removes existential risk and validates a contrarian investment stance, driving a sharp stock price recovery. A key investment thesis now hinges on UGN-102's commercial uptake, as physician adoption versus entrenched surgical standards remains uncertain. UroGen's financial runway is limited, with high cash burn and royalty obligations, raising the likelihood of future capital raises or non-dilutive financing.
US FDA approves Urogen's bladder cancer drug
The U.S. Food and Drug Administration has approved Urogen Pharma's drug to treat a type of bladder cancer, the regulator said on Thursday.
UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation
PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The 7 major bladder cancer markets are expected to reach $5.4 billion by 2034. Company is developing anti-CTLA4 antibody UGN-301 in a phase 1 study either alone as a monotherapy or in combination to target patients with recurrent high-grade non-muscle invasive bladder cancer.
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral.
UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either
UroGen Pharma Ltd.'s investment thesis hinges on FDA approval of UGN-102, a minimally invasive bladder cancer treatment with a June 13 decision date. ODAC narrowly voted against approval, citing insufficient comparative data, but a split panel and urologist support leave room for a positive FDA surprise. URGN faces significant financial risk, with only 4-5 quarters of cash and inability to fund another confirmatory trial if required by the FDA.
UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2025 Earnings Conference Call May 12, 2025 10:00 AM ET Company Participants Vincent Perrone - Senior Director, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Chris Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Kelsey Goodwin - Guggenheim Leland Gershell - Oppenheimer Raghuram Selvaraju - H.
